Mircea Dediu

12.0k citations
55 papers · 6.8k · 4 hit papers · h-index 19

Impact in

    • Lung Cancer Treatments and Mutations
    • Lung Cancer Diagnosis and Treatment
  • Oncology top 0.5%
    • Lung Cancer Research Studies
    • Colorectal Cancer Treatments and Studies
    • HER2/EGFR in Cancer Research
    • Cancer Immunotherapy and Biomarkers

Papers in

    • Lung Cancer Treatments and Mutations 32
    • Lung Cancer Diagnosis and Treatment 13
    • Lung Cancer Research Studies 13
    • HER2/EGFR in Cancer Research 5
    • Colorectal Cancer Treatments and Studies 4

Mircea Dediu

52 papers receiving 6.6k citations

Mircea Dediu's Hit Papers

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial 2015 · 355 citations
3550+7+14Years since publication10002.0k3.0k4.0k

Peers

Mircea Dediu
Comparison fields: 5 of 99
  • Pulmonary and Respiratory Medicine 4.2k
  • Oncology 3.2k
  • Cancer Research 699
  • Molecular Biology 1.3k
  • Hepatology 125
Replace Renato Martins with:
Renato Martins United States
José Rodrigues Pereira Brazil
Haruyasu Murakami Japan
Daniel de Castro Spain
Sarayut Lucien Geater Thailand
В. А. Горбунова Russia
Chun‐Ming Tsai Taiwan
David M. Jackman United States
Hiroshi Nokihara Japan
Makoto Maemondo Japan
Mircea Dediu relative to Renato Martins United States Renato Martins's profile →
Citations per field
00.5×1.5×
Renato Martins · 1×
Citations per year

Countries citing papers authored by Mircea Dediu

Since Specialization
Citations

This map shows the geographic impact of Mircea Dediu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mircea Dediu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mircea Dediu more than expected).

Fields of papers citing papers by Mircea Dediu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mircea Dediu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mircea Dediu. The network helps show where Mircea Dediu may publish in the future.

Co-authors

The 25 scholars most cited alongside Mircea Dediu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mircea Dediu Line = papers co-authored together Mircea Dediu links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 55 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Hit paper breakdown →
20054412
2
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial
Hit paper breakdown →
2012457
3
PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer
Hit paper breakdown →
2013456
4
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
Hit paper breakdown →
2015355
5 2009195
6 2009161
7 2012149
8 201485
9 200965
10 201241
11 201040
12 201435
13 201434
14 201132
15 200927
16 201024
17 201720
18 201419
19 201418
20 201617

About Mircea Dediu

Mircea Dediu is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Surgery, Molecular Biology and Radiology, Nuclear Medicine and Imaging, having authored 55 papers that have together received 6.8k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (32 papers), Lung Cancer Diagnosis and Treatment (13 papers), Lung Cancer Research Studies (13 papers), HER2/EGFR in Cancer Research (5 papers), Colorectal Cancer Treatments and Studies (4 papers), Cancer Genomics and Diagnostics (3 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and Cancer therapeutics and mechanisms (3 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (4.2k citations), Oncology (3.2k citations), Cancer Research (699 citations), Molecular Biology (1.3k citations) and Hepatology (125 citations). Mircea Dediu has collaborated with scholars based in Romania, Germany and United States. Frequent co-authors include Tudor–Eliade Ciuleanu, Lesley Seymour, Frances A. Shepherd, José Rodrigues Pereira, Maximiliano Van Kooten, Michael Smylie, Renato Martins, B. Findlay, Dongsheng Tu and D. Johnston. Their work appears in journals such as Journal of Clinical Oncology, Lung Cancer, Annals of Oncology, Journal of Thoracic Oncology and Value in Health.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact